Paradoxical attenuation of neuroinflammatory response upon LPS challenge in miR-146b deficient mice

Keerthana Chithanathan, Monika Jürgenson, Mithu Guha, Ling Yan, Tamara Žarkovskaja, Martin Pook, Nathaniel Magilnick, Mark P. Boldin, Ana Rebane, Li Tian and Alexander Zharkovsky*

The miR-146 family consists of two microRNAs (miRNAs), miR-146a and miR-146b (miR-146a/b), both of which are known to suppress immune responses in a variety of conditions. Here, we studied how constitutive deficiency of miR-146b (Mir146b-/-) affects lipopolysaccharide (LPS)-induced neuroinflammation in mice. Our experiments demonstrated that miR-146b deficiency results in the attenuation of LPS-induced neuroinflammation, as it was evidenced by the reduction of sickness behavior, a decrease in the inflammatory status of microglia, and the loss of morphological signs of microglial activation in the hippocampus. Gene expression analysis revealed that LPS-induced upregulation of hippocampal pro-inflammatory cytokines is attenuated in Mir146b-/- mice, compared to wild-type (WT) mice. In addition, reduced expression of the NF-κB nuclear protein p65, reduced miR-146 family target TLR4 expression and relatively stronger upregulation of miR-146a was found in Mir146b-/- mice as compared to WT mice upon LPS challenge. Compensatory upregulation of miR-146a can explain the attenuation of the LPS-induced neuroinflammation. This was supported by experiments conducted with miR-146a/b deficient mice (Mir146a/b-/-), which demonstrated that additional deletion of the miR-146a led to the restoration of LPS-induced sickness behavior and proinflammatory cytokines. Our experiments also showed that the observed upregulation of miR-146a in Mir146b-/- mice is due to the overexpression of a miR-146a transcription inducer, interferon regulatory factor 7 (Irf7). Altogether, our results show the existence of crosstalk between miR-146a and miR-146b in the regulation of LPS-induced neuroinflammation.

KEYWORDS
miRNAs, miR-146b deficiency, attenuated neuroinflammation, miR-146a upregulation, miR-146a/b crosstalk
Introduction

Neuroinflammation is considered as an important contributing factor in various central nervous system disorders, including neuropsychiatric disorders and neurodegenerative diseases, such as major depression, schizophrenia, Alzheimer’s disease, and Parkinson’s disease (1–5). During inflammation, the termination phase is crucial to prevent tissue damage. For that, effective resolution programs are needed to prevent the progression of persistent inflammation (6). In this regard, several microRNAs (miRNAs) have been demonstrated to have a critical role in controlling inflammation (7). miRNAs are endogenous, small non-coding RNAs with ~22 nucleotides in length, which regulate gene expression via imperfect base-pairing with the 3’-untranslated regions (3’-UTR) of multiple target mRNAs and thereby inhibit mRNA and protein expression (8). Individual miRNAs can affect different aspects of innate as well as adaptive immune cell development and functions (9). Several miRNAs have emerged as regulators of neuroinflammation, among which miR-155 has been shown to promote (10) and the miR-146 family to suppress neuroinflammation (11, 12).

The miR-146 family of miRNAs consists of two members, miR-146a and miR-146b (miR-146a/b), which differ only in two nucleotides and are encoded by two distinct genes located on chromosomes 5 and 10, in the human genome and on chromosome 11 and 19 in the mouse genome, respectively (13). As miR-146a/b have identical seed sequences, they can probably target the same or very similar set of genes (13, 14). Both miR-146a/b have been shown to negatively regulate the nuclear factor kappa B (NF-κB) pathway through multiple targets such as the TNF receptor-associated factor 6 (TRAF6) and interleukin-1 receptor-associated kinase 1 (IRAK1) (15). Correspondingly, miR-146a/b have been shown to suppress innate immune responses in cell culture conditions (16) and in vivo in mice, as demonstrated by the exaggerated inflammatory response of miR-146a knockout mice upon administration of lipopolysaccharide (LPS) (17, 18). The lack of miR-146a or miR-146b also leads to changes in adaptive immune responses, as more prominent Th helper (Th)1/Th17 responses have been revealed in these mice in different disease models (19–21).

In the central nervous system, miR-146a is abundantly expressed in microglial cells (22, 23). Numerous lines of genetic evidence suggest that polymorphisms in miR-146a can influence its function and thereby contribute to susceptibility to several neurological diseases (24, 25). In addition, miR-146a is upregulated in age-related inflammatory neurodegenerative disorders, including Parkinson’s disease (26), Alzheimer’s disease (27), viral encephalitis (28), and epilepsy (29).

In contrast to miR-146a, very few studies have addressed miR-146b function in the regulation of neuroinflammation in the central nervous system. Overexpression of miR-146b was shown to inhibit inflammatory responses via suppression of the activation of the NF-κB signaling in the brain in rat encephalopathy models (30). Another study showed that treatment of microglial cells with LPS led to increased expression of miR-146b but not miR-146a, while transfection of miR-146b into microglial cells significantly decreased LPS-induced microglial activation and downregulated IRAK1 (31). Intriguingly, we reported that constitutive miR-146b deficiency didn’t cause microglial activation or signs of neuroinflammation in the hippocampus of the mouse brain (22). However, knowledge on the regulation of neuroinflammation in the absence of miR-146b is still lacking.

Hereby, we used Mir146b−/− mice to study the role of miR-146b in neuroinflammation upon LPS challenge. Interestingly, we observed blunted neuroinflammatory response in miR-146b deficient mice subjected to LPS treatment which may be due to the elevated miR-146a level, causing downregulation of inflammatory factors.

Materials and methods

Animals

Two-three months old male C57BL/6J WT, Mir146b−/− and Mir146a/b−/− were housed and bred in laboratory animal facility at the Institute of Biomedicine and Translational Medicine, University of Tartu under standard conditions as previously described in (14). Mir146b−/− and corresponding WT mice used for this study were obtained by crossing Mir146b−/+ heterozygous mice. The Mir146a/b−/− mouse line was created by crossing Mir146b−/− and Mir146a−/− lines. The generated animals were genotyped using the following primer sequence: 146b locus 5′ forward primer- 5′ CTACACTGTTTCTTACCCAGTTCTT 3′; 146b locus 3′ reverse primer- 5′ CCAACCAACAACAAAAGGTTCCAGCTAAG 3′; 146b locus internal reverse primer- 5′ ACACACAGGGGCTATGA GATCAGTTGGT 3′; 146a forward primer- 5′ ACCAGCAGTCCTCTTGATGC 3′; 146a reverse primer- 5′ GACGAGCTGTCTCAAGTTCCC 5′ and same generation littermates were used in experiments. All experiments were undertaken in agreement with the guidelines established in the Principles of Laboratory Animal Care (Directive 2010/63/EU) and the mice were group-housed with a 12h light/dark cycle with food and water available ad libitum. The Animal Experimentation Committee at the Estonian Ministry of Agriculture (no. 183 and 158, 2021) approved the experimental protocol.

Experimental plan

Male WT (n = 40) and Mir146b−/− mice (n = 44), were randomly assigned to different experimental groups. The first
cohort (WT $n = 12$, Mir146b-/− $n = 13$) was used to measure bodyweight, locomotor activity and sickness behavior after LPS or saline administration during the 20h period and animals were sacrificed at 24h. This cohort was used to determine LPS-induced genotypic differences in microglial profile by flow cytometry. The second cohort (WT $n = 12$, Mir146b-/− $n = 13$) was used for gene expression analysis, miRNA quantification and Western blot, besides behaviors. The third cohort (WT $n = 10$, Mir146b-/− $n = 12$) was used for morphological analysis of ionized calcium binding adaptor molecule 1 (Iba-1) positive cells by immunohistochemistry. Fourth cohort (WT $n = 6$, Mir146b-/− $n = 6$) was used for isolation of microglial cells after LPS administration. In addition, Male WT ($n = 10$) and Mir146a/b-/− mice ($n = 10$) was used to measure sickness behavior after LPS or saline administration followed by gene expression analysis. The sequence of the experiments performed is summarized in Figure 1.

**LPS treatment**

LPS (derived from E. coli serotype O55: B5; Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.9% NaCl (saline). In each animal cohort, one group was injected intraperitoneally (i.p.) with 1.5 mg/kg bodyweight of LPS solution and another group received injection of an equal volume of saline as controls. For isolated microglial cells from WT mice, 1 µg/mL of LPS for 4 h was used for stimulation.

**Body weight measurement and assessment of locomotor activity**

Bodyweight was measured before and 24 h post LPS or saline injection in WT and Mir146b-/− mice. The effect of LPS on locomotor activity was monitored for 60 or 30 min by using PhenoTyper apparatus (Noldus, Leesburg, VA) with Ethovision XT live videotracking software (Version 8.0, Noldus Information Technologies, Leesburg, VA). Total distance traveled in the whole arena was measured.

**Tail suspension test**

Tail suspension test was performed as previously described (32). In separate compartments of the wooden test apparatus, each mouse was suspended by the tail to a wooden beam with an adhesive tape. The total duration of immobility time during the 6 min testing period was measured manually by using stopwatch. Immobility was defined as a complete lack of movement other than respiration, small movements of forefeet and swinging caused by earlier movements.

**Flow cytometry**

Flow cytometry was conducted according to the validated method published previously (33, 34). Mice were euthanized with CO2 and the brain tissues were dissected out. Isolation of cells were made by homogenizing the tissues through 70 µm cell strainers (#352350, BD Bioscience) in ice-cold flow buffer (PBS with 1% fetal calf serum). Cells were blocked with 10% rat serum in ice-cold PBS for 1 h and stained with 0.5 µl anti-mouse CD11b-Brilliant Violet 421 (cat no. 101251, Biolegend), CD45-Brilliant Violet 650 (cat no. 103151, Biolegend), MHCII-Brilliant Violet 711 (cat no. 107643, Biolegend), CD115-Brilliant Violet 605 (cat no. 135517, Biolegend), Glast-APC (cat no. 130-123-555, Miltenyi) with the corresponding isotype control antibodies (all from BioLegend) rat IgG2b-BV421 (#400639), rat IgG2b-BV650 (#400651), rat IgG2b-BV711 (#400653), rat IgG2a-BV605 (#400539) and mouse IgG2a-APC (#400219) in flow buffer for 1h. Cells were then fixed by 4% paraformaldehyde followed by permeabilization with 0.05% TritonX-100 in PBS at 4°C. After washings, cells were incubated with an anti-VGLUT2 mAb-Alexa488 (# MAB5504A4 Millipore) or isotype ctrl mAb-Alexa488 (#400132 Biolegend) for 1h at 4°C. Washed and resuspended cells were acquired with a Fortessa flow cytometer (BD Bioscience). Data were analyzed by Kaluza v2.1 software (Beckman Coulter). The cell viability was assessed using CytoTell orange (Cat. No. 22257, AAT Bioquest, US) and respective plots are shown in Supplement Figure 2A. Microglial cells were gating was based on the expression levels of CD11b and CD45 markers. Within the CD11b+CD45+...
population, we gated CD11b+CD45intermediate as microglia and CD11b+CD45high as macrophages.

Immunohistochemistry of Iba1

After 24 h of LPS administration, animals were deeply anesthetized with chloral hydrate (300 mg/kg, i.p.) and transcardially perfused using 0.9% saline and then with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS, pH = 7.4). The brains were kept in PFA solution for 72 h to reduce unspecific binding to endogenous biotin and 40 µm-thick sections were cut on a Leica VT1000S vibro-microtome (Leica Microsystems Pvt Ltd., Wetzlar, Germany) and stored at −20°C in the cryo-protectant (30% ethylene glycol, 30% glycerol in PBS: pH 7.4).

Before staining, the sections were washed three times in PBS and treated with 2% H2O2 solution for 20 min followed by incubation in 0.01 M citrate buffer (pH 6.0) at 85°C for 30 min in water bath and then stood for 30 min at room temperature. Another wash was done in PBS containing 0.1% Triton X-100. Blocking was done with solution containing 5% goat serum, 0.5% Tween-20, 0.25% Triton X-100 in 100 mM PBS for 1 h. Iba1 primary antibody (1: 700, rabbit anti-Iba1, CA6806, FUJIFILM Wako Chemicals Europe GmbH, Neuss, Germany) was added in blocking buffer for 72 h. After being washed three times, the sections were incubated with secondary antibody (1:700, affinity purified goat anti-rabbit biotinylated IgG (H +L), Vector Laboratories) in blocking buffer at room temperature for 1 h. Iba1-positive cells were visualized using peroxidase method (ABC system and diaminobenzidine as chromogen, Vector Laboratories). The sections were dried, cleared with xylol and cover-slipped with mounting medium (Vector Laboratories, Newark, CA, USA). To control unspecific binding, some sections were used as negative controls, where incubation step with the primary antibody was omitted.

The morphological characteristics of Iba1+ microglia (cell size, cell body size, size dendritic processes), were analyzed using image analysis software (ImageJ 1.48v, http://imagej.nih.gov/ij), an algorithm previously described (35) was used. Briefly, images were converted into binarized 8-bit format and “adjusted threshold” and “analyze particles” functions were used to apply intensity thresholds and size filter. To measure the total cell size, the threshold was maintained at the level that was automatically provided by the ImageJ program, and size filter of 150 pixels was applied. To measure the total cell body size, the threshold was lowered by 40 points and no size filter was applied. The counts of Iba-1 positive cells were obtained from images according to the algorithm described previously (36) using “analyze particles” command in ImageJ software.

Isolation of microglia

Brain cells were isolated as previously described (37). Tissues were mechanically homogenized and passed through a 70 µm nylon cell strainer (352350, BD Bioscience) with approximately 10–15 ml of 1X DPBS supplemented with 0.2% glucose into a 50 ml conical tube. Isotonic percoll dilutions were made by diluting stock percoll (GE-healthcare, 17-0891-01, Chicago, IL, USA) at a 9:1 ratio with 10X PBS to make stock isotonic percoll (SIP), which is considered 100% SIP. The layers of percoll were created by diluting the 100% SIP with 1X Dulbecco’s phosphate buffered saline (DPBS) to make 70% SIP, 50% SIP and 35% SIP. Obtained homogenate was then centrifuged at 600× g for 6 min at room temperature. Supernatant was decanted and the pellet resuspended in 6 ml of the 70% SIP. Resuspended homogenate was transferred to a 15 ml tube and 3 ml of the 50% SIP was carefully layered over. Another 3 ml of the 35% SIP was carefully layered on top of the 50% SIP layer, and 2 ml of 1X DPBS was layered on top of the 35% layer. The prepared 15ml tubes were then centrifuged at 2000× g for 20 min at room temperature without brake. Three discrete layers were established after centrifugation. Microglial cells were collected from the interface between the 50–70% SIP. Isolated microglial cells were resuspended in sterile 1X DPBS and centrifuged at 600× g for 6 min at room temperature to remove any remaining percoll. Washed cells were subjected to qPCR and flow cytometry methods to check purity of isolated microglial cells.

Total RNA isolation, real-time quantitative PCR and absolute quantification by digital PCR

Total RNAs were extracted from brain tissues (hippocampus) by using TRI Reagent® (TR 118) (Molecular Research Center, Inc., Cincinnati, OH, USA). To measure mRNA expression, cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) followed by qPCR using 5 × HOT FIREPol® EvaGreen® qPCR Supermix (Solis BioDyne, Tartu, Estonia) on a QuantStudio 12KFlex instrument (Thermo Fisher Scientific) according to the instructions of the respective manufacturers. Primer sequences for target genes were given in the Supplement Table 1. Absolute quantification of microRNAs was carried out according to the manufacturer’s instructions (Qiagen) using miRCURY LNA RT Kit (Cat. No. 339340) for cDNA synthesis and miRCURY LNA PCR Assays (Assay IDs: YP00204688, YP02119310) in combination with QI Acuity EG PCR Kit (Cat. No. 250111) for detection of miR-146a and miR-146b. The samples were run and analyzed on QIAcuitly One dPCR System using QIAcuity
Protein content of nuclear fractions were measured using TaqMan® MicroRNA Assays hsa-miR-146a (Assay ID: 000468, Life technologies) and TaqMan® MicroRNA Assays hsa-miR-146b (Assay ID: 001097, Life technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. For cRNA synthesis, TaqMan® MicroRNA reverse transcription kit (4366596, Thermo Scientific) and for qPCR, 5× HOT FIREPol® Probe qPCR Mix Plus (ROX) (Solis BioDyne) were used, respectively. U6 snRNA (Assay ID: 001973, Life Technologies) was used for the normalization of RT-qPCR. To analyze relative mRNA expression, ΔΔCt calculations was used. As housekeeping genes for normalization, Gapdh was used. The data were analyzed in relative to the mean value of one of the samples as a calibrator (control sample or WT saline), which was normalized to 1 and the rest of the samples were compared against the control sample.

Western blot

Western blotting of Iba1 and toll-like receptor-4 (TLR4) protein was performed as described previously (38). Hippocampal tissues (15-20 mg) were lysed in a lysis buffer (#ab113474; Abcam, UK) for protein extraction. The protein concentration was determined using the Bradford reagent kit (#B6916; Sigma-Aldrich, Germany). For Western blot analysis, 20 µg of total protein for TLR4 or Iba-1 detection was dissolved in 15% sodium dodecyl sulfate polyacrylamide gels and transferred electrophoretically onto a nitrocellulose membrane (Merck Millipore, US). The membranes were blocked with Intercept (TBS) Blocking Buffer (Li-Cor Biosciences, US) for 60 min at room temperature (RT). Then, the blots were incubated for 48 h at 4°C with the primary antibody for Iba1 (Rb, #ab178846, 1:1000; Abcam, UK) or TLR4 (Ms, #sc-293072, 1:500; Santa Cruz Biotechnology, USA) and after washing thrice with TBST (50 mmol/L Tris, pH 7.6; 0.9% NaCl; and 0.1% Tween-20), the membranes were incubated with the secondary antibody (IRDye800, aRb, #C40721-02, 1:1000; Li-Cor Biosciences) for 1 h at RT. Loading control β-actin was detected by incubating membranes overnight with monoclonal anti-β-actin antibody (Ms, #039M4768V, 1:10000; Sigma-Aldrich, US), followed by incubation with IRDye conjugated secondary antibody (IRDye680LT, aMs, #C60301-03, 1:1000; Li-Cor Biosciences). After extensive washing with TBST, the Odyssey Infrared Imaging System (Li-Cor Biosciences) was used for antibody detection and quantification. The ratios of Iba1 or TLR4 protein to β-actin were calculated and expressed as the mean optical density ratio in arbitrary units.

For NF-κB p65 protein in the nuclear fraction was performed as follows. Nuclear extract was prepared from the hippocampal tissues according to manufacturer’s protocol (Abcam nuclear extraction kit, ab113474) using 20 mg tissue. Protein content of nuclear proteins were measured using Bradford reagent (Sigma, B6916). Equivalent amounts of proteins were resolved on 10% polyacrylamide gels by SDS-PAGE. Resolved proteins were transferred to Immobilon® FL membrane (IPFL00010, Millipore) in 0.1 M Tris-base, 0.192 M glycine and 20% (w/v) methanol using an electrophoretic transfer system with cold-block. The membranes were blocked using Odyssey blocking buffer (LICOR Biosciences, 927–40000) at room temperature for 1 h. After blocking, the membranes were incubated sequentially overnight with different primary antibodies anti rabbit NF-κB p65 (Abcam antibody, ab 16502), anti-rabbit histone-4 antibody to mark the nuclear fraction (Abcam antibody, ab 10158), anti-mouse beta-tubulin antibody to show no cytoplasmic contamination in nuclear fractions (Millipore, MAB1637). Incubations were followed by 3 times washing in Tris Buffered Saline containing 0.1% Tween-20 followed by incubation with the appropriate secondary antibody (1:10000), either goat anti-rabbit IRDye 800CW or 680LT or goat anti-mouse IRDye 680LT (all from Licor Biosciences), for 2 h at room temperature. Immuno-reactive bands were detected by the Odyssey Infrared Imaging System. Densitometry analysis of protein bands were done by Image studio Ver 2.0. Ink.

Statistical analysis

GraphPad 8.0.1 (San Diego, CA, United States) was used for statistical analyses and graphical presentations. The following steps of statistical evaluation of the data were undertaken. All data sets were tested for homogeneity of variances using the Brown-Forsythe test and for normal distribution using the Shapiro-Wilk test. If the data sets passes both the tests then they were processed using two-way ANOVA followed by Tukey multiple comparisons test. If data sets did not pass a test for homogeneity of variances, they were processed using Welch’s ANOVA followed by Dunnett’s test. If the data did not pass the Shapiro-Wilk test, they were transformed into logarithms (Y=Log(Y)) and processed further using one-way ANOVA followed by Tukey multiple comparisons test. The appropriate statistical test for each data set is specified in the figure legends. Statistical significance was set at p < 0.05, and data were reported as mean ± SEM.

Results

Expression profile of miR-146a/b upon LPS in the hippocampus and microglial cells isolated from the mouse brain

To better understand the importance of miR-146a/b in neuroinflammation, we first measured the expression levels of miR-146a/b in the hippocampus of WT mice upon LPS
treatment using RT-qPCR method that enables absolute quantification. In hippocampal tissues, basal levels of miR-146a/b were similar, and after LPS administration both miR-146a (p = 0.0013) and miR-146b (p = 0.0170) were significantly induced at 24 h time point. The upregulation of miR-146a was apparently stronger, compared to miR-146b (p = 0.0836) (Figure 2A). Next, we evaluated expression of miR-146a/b in microglial cells isolated from the WT mouse brain. Purity of isolated microglia is shown in Supplement Figure 1. In microglial cells, the basal expression of miR-146a was several folds higher than that of miR-146b, while upon LPS challenge, both miR-146a (p = 0.0340) and miR-146b (p = 0.0342) were upregulated (Figure 2B). Significant effects of LPS treatment (F (1.8) = 6.475, p = 0.0345), miR expression (F(1,8) = 20.97, p = 0.0018), and interaction (miR expression × treatment: F(1,8) = 5.629, p = 0.0451) existed. Altogether, these data demonstrate that miR-146a was over 37-fold more highly expressed in microglial cells under basal conditions, and that both miR-146a/b were induced upon LPS treatment in the hippocampus and microglial cells of mouse brain. In contrast, the level of induction of miR-146b was little more prominent than miR-146a in microglial cells.

LPS-induced reduced sickness behavior in Mir146b-/− mice

We have previously demonstrated that Mir146b-/− mice did not differ from WT animals with regard of body weight, locomotor activity, food and water consumption, hippocampal and total brain volumes at the age of 2-3 months (22). It is known that systemic administration of LPS in animals leads a behavioral state called “sickness behavior”, which is characterized by lethargy, decreased locomotor activity and appetite, depression-like behavior, and increased sensitivity to pain (39). To evaluate the impact of miR-146b on the LPS-induced sickness behavior, we treated Mir146b-/− and WT mice with LPS and assessed the locomotor activity, loss of body weight and immobility time in tail suspension test.

We first evaluated changes in body weight before and 24 h after a high dose administration of LPS (1.5 mg/kg) and observed that LPS induced a decrease in body weight in both WT and Mir146b-/− mice (Welch’s ANOVA (F(3,40.12) = 120.3, p < 0.0001). Dunnett’s test revealed a significant effect (p < 0.001) of LPS treatment in both WT and Mir146b-/− mice. However, LPS-induced body weight loss was slightly less prominent in Mir146b-/− mice than that observed in WT mice (p = 0.07) (Figure 3A).

Next, reductions in locomotor activity were observed in both WT and Mir146b-/− mice after LPS treatment (Welch’s ANOVA F(3,21.5) = 50.01, p < 0.0001). Dunnett’s test demonstrated a significant reduction in locomotor activity in WT (p < 0.0001) and in Mir146b-/− mice (p < 0.001), whereas Mir146b-/− mice demonstrated a significantly (p < 0.01) less reduction in locomotor activity upon LPS challenge as compared with WT mice (Figure 3B).

Furthermore, we evaluated the development of depression-like behavior as evidenced by immobility time in the tail suspension test and observed increased immobility time upon LPS treatment (Welch’s ANOVA demonstrated a highly significant effect of LPS (F(3,23.1)=17.19, p < 0.0001). Post hoc analysis revealed a significant enhancement of immobility in WT mice upon LPS challenge (p < 0.0001). In contrast, no enhanced immobility was observed in Mir146b-/− mice compared to the untreated group (Figure 3C).

In conclusion, LPS-induced sickness behavior manifested by the rapid decrease in body weight, reduction in locomotor activity and increased sensitivity to pain was more pronounced in WT mice compared to Mir146b-/− mice.
activity and development of depression-like behavior was less severe in \textit{Mir146b-/-} mice as compared with WT littermates.

LPS induced less activation in microglial morphology and Iba1 protein levels in \textit{Mir146b-/-} mice

LPS is known to act through the innate immune toll-like 4 (TLR4) to induce an innate immune response, which causes, among other symptoms, sickness behavior. TLR4 is highly expressed in brain microglia, and excessive inflammation resulting from activation of this pathway in the brain has been implicated in various brain pathologies (40). Therefore, we next evaluated LPS-induced microglial activation by assessing their profiles of morphological changes. To do that, we stained the brain sections from WT and \textit{Mir146b-/-} mice with antibody against Iba1, a marker for microglia (Figure 4A) and assessed microglial morphometrics, such as average cell size, cell body size and size of dendritic processes.

Our results demonstrated that LPS administration induced trends of increase in microglial density in both WT and \textit{Mir146b-/-} mice (Figure 4B). Significant effect of LPS treatment ($F(1,17) = 13.18$, $p = 0.0021$) but not genotype and interaction were observed.

Next, we assessed microglial cell size (Figure 4C), cell body size (Figure 4D), and size of the dendritic processes (Figure 4E) separately. We detected increased values of all these parameters upon LPS challenge in both WT and \textit{Mir146b-/-} mice, but which were less pronounced in \textit{Mir146b-/-} mice compared to WT group. For average cell size, significant effects existed for LPS treatment ($F(1,17) = 119.3$, $p < 0.0001$), genotype ($F(1,17) = 11.60$, $p = 0.0034$), and interaction ($F(1,17) = 11.25$, $p = 0.0038$). For average cell body size, significant effects of LPS treatment ($F(1,17) = 296.1$, $p < 0.0001$), genotype ($F(1,17) = 8.795$, $p = 0.0087$), and interaction ($F(1,17) = 6.604$, $p = 0.0199$) also existed. For size of the dendritic processes, effects of LPS treatment ($F(1,17) = 91.33$, $p < 0.0001$), genotype ($F(1,17) = 10.27$, $p = 0.0052$), and interaction ($F(1,17) = 10.20$, $p = 0.0052$) were significant as well.
Microglial morphology and Iba1 protein levels upon LPS challenge in the hippocampus of miR-146b deficient and WT mice. Mice were injected with LPS in saline or equal volume of saline (control) followed by harvesting the tissues and immunohistochemistry. (A) Representative immunohistochemistry microphotographs of the hippocampal Iba1+ cells at 400x magnification. (B) Density of microglial cells. (C) Average cell size. (D) Average cell body size and (E) Size of dendritic processes of microglial cells in hippocampus of WT and Mir146b-/- mice upon LPS treatment. Number of animals = 5–6. Scale bar = 50 µm. Data are represented as mean ± SEM; ** p < 0.01, **** p < 0.0001 (Two-way ANOVA with Tukey’s multiple comparison test). For western blot, hippocampal lysates from LPS or saline injected WT and Mir146b-/- mice were probed for Iba1 protein. (F) Representative immunoblot for Iba1 protein. (G) Densitometry quantification of Iba1. Number of animals = 4. Data are represented as mean ± SEM; * p<0.05 (Welch’s ANOVA with Dunnett’s multiple comparisons test).
In addition, we measured LPS-induced changes in Iba1 protein levels in the hippocampus of Mir146b-/− and WT littermates (Figures 4F, G). For Iba1 protein levels Welch’s ANOVA demonstrated significant effect (F(3,5,1) = 10.58, p = 0.028). Post hoc analysis demonstrated a significant increase in Iba1 protein upon LPS challenge in WT animals, but no significant changes were observed in Mir146b-/− mice (Figure 4G).

These results together demonstrated that LPS-induced activation of microglia, manifested by increased cell size, cell body size and size of the dendritic processes, was less pronounced in Mir146b-/− mice as compared to WT mice.

LPS induced changes in microglial profile in Mir146b-/− mice

We next tested whether systemic administration of LPS induces a different microglial profile in WT and Mir146b-/− mice using flow cytometry of hippocampus tissue 24 h after LPS or saline administration. A combination of cell-specific markers was used to identify CD11b+CD45 intermediate as microglia and CD11b+CD45 high as macrophages and representative isotypic controls are shown in (Supplement Figure 2B). Representative gating strategy for quantification of microglial percentage is shown in (Figure 5A) and we found increased percentage of microglia (p = 0.0027) upon LPS activation in WT mice, but not in Mir146b-/− mice (Figure 5B), with significant effect of LPS treatment (F(1,20) = 12.81, p = 0.0019), genotype (F(1,20) = 15.63, p = 0.0008) and interaction (F(1,20) = 5.150, p = 0.0345) being observed. The percentage of macrophages were elevated in the hippocampus in both WT (p = 0.0430) and Mir146b-/− mice (p = 0.0013) after LPS administration (Figures 5C, D) too, with significance in the effect of LPS treatment (F(1,20) = 26.22, p < 0.0001) but not genotype and interaction.

To assess the activation level of microglial cells after LPS stimulation, percentage of major histocompatibility complex II (MHC-II)-positive M1-type of pro-inflammatory microglia and mean fluorescence intensity (MFI) level of CD11b were measured. CD11b is constitutively expressed by microglia, but its expression is increased upon activation (41–43). The percentage of MHCII expressing microglia were significantly higher in WT LPS group (p = 0.0142) and Mir146b-/− LPS (p = 0.0131) compared to their respective controls (Figure 5E). Significance of LPS treatment (F(1,22) = 22.69, p < 0.0001) but not genotype and interaction were observed. As expected, the MFI level of CD11b was significantly higher after administration of LPS in both WT (p < 0.0001) and Mir146b-/− mice (p < 0.0001). No significant difference between the WT LPS and Mir146b-/− LPS groups was detected. However, the basal level of CD11b was lower in Mir146b-/− mice compared to WT mice (p = 0.0056) (Figure 5F), indicating reduced basal activation of Mir146b-/− microglia. Statistical analysis revealed significant effect of LPS treatment (F(1,22) = 132.2, p < 0.0001), genotype (F(1,22) = 9.717, p = 0.0050), and interaction (F(1,22) = 5.700, p = 0.0260). Altogether, these results suggest that microglial cells in Mir146b-/− mice showed less activation as compared to WT mice.

We also investigated the expression of macrophage colony-stimulating factor 1 receptor, Csfr1 (CD115) on microglial surface. CSF1R signaling is essential for microglial survival, proliferation, and differentiation (44–47). Altered expression of CSF1R in microglia have been identified in many neuroinflammatory diseases (48, 49). An in vivo study had shown that inhibition of CSF1R attenuated neuroinflammation and reduced microglial proliferation in a murine acute LPS model (50). We found that LPS induced an increase in (p = 0.0411) Csfr1 expression in the hippocampus of WT mice but decreased its expression in Mir146b-/− mice (p < 0.0001). Notably, the basal level of Csfr1 was higher in Mir146b-/− mice compared to WT mice (p < 0.0001) (Figure 5G). Statistical analysis showed significant effects of genotype (F(1,22) = 4.535, p = 0.0446) and interaction (F(1,22) = 36.05, p < 0.0001) but not LPS treatment. Altogether, flow cytometry analysis results indicate that microglia of miR-146b deficient mice were less activated and more resistant to LPS treatment.

LPS induced changes in microglia-mediated phagocytic activity in Mir146b-/− mice

LPS-induced neuroinflammation has been linked to enhanced phagocytosis (51). Phagocytosis is an event, which has been associated with an anti-inflammatory profile of activated microglia (52). Therefore, we evaluated the microglial phagocytic activity upon LPS challenge in Mir146b-/− mice using intracellular staining Vglut2, a glutamatergic pre-synapse-specific protein, by flow cytometry similarly as performed before in (34, 53). Gating strategy with representative dot plots are presented in (Figure 6A). Statistical analysis revealed that Mir146b-/− mice have significantly higher percentage of Vglut2+ microglia than WT mice (p = 0.0062) in basal conditions suggesting that miR-146b deficiency results in an increased phagocytic activity of microglia. Upon LPS treatment, we observed higher levels of Vglut2 engulfment in WT mice (p = 0.0029), whereas Mir146b-/− mice showed a decrease in percentage of Vglut2+ microglia (p = 0.0033) (Figure 6B) compared to their controls. Statistical analysis revealed no significant effect of LPS treatment (F(1,22) = 0.57, p = 0.46) and genotype (F(1,22) = 0.23, p = 0.63) and highly significant effect of interaction (LPS x genotype, F(1,22) 24.59, p < 0.0001). These results together suggest that miR-146b deficiency reduces microglial ability to be converted into phagocytic phenotype upon LPS treatment.
LPS induced changes in cytokine gene expression in Mir146b-/− mice

To answer the question whether reduced ability of LPS to induce neuroinflammation in Mir146b-/− mice was associated with changes in mediators of neuroinflammation, we evaluated mRNA expressions of genes encoding pro-inflammatory cytokines (Il1b, Il18, Tnf, Il6, and ccl5), anti-inflammatory cytokines (Il10 and Il13), and NLRP3 inflammasome component (Nlrp3). Under basal conditions, the mRNA expression levels of these genes did not significantly differ between WT and Mir146b-/− mice. However, the marked differences between genotypes appeared upon LPS administration (Figure 7).
LPS administration induced increased expression of Il1b and Ccl5 mRNAs in WT mice, while in Mir146b-/− mice Il1b mRNA levels remained unchanged and Ccl5 mRNA levels showed an increase in response to LPS (Figures 7A, B). A significant effect of LPS treatment on Il1b and Ccl5 mRNA expression \((F(1,24) = 15.40, p = 0.0006; F(1,24) = 69.70, p < 0.0001)\) was found.

Similarly, administration of LPS increased expression of Il18 \((p = 0.0019)\) and Tnf \((p < 0.0001)\) mRNAs in WT mice, while Il18 remained resistant \((p = 0.7802)\) and Tnf was slightly increased \((p = 0.0257)\) in Mir146b-/− mice upon LPS administration (Figures 7C, D). Significant effects of LPS treatment \((F(1,24) = 12.96, p = 0.0014; F(1,24) = 51.85, p < 0.0001)\), genotype \((F(1,24) = 4.739, p = 0.0392; F(1,24) = 27.64, p < 0.0001)\), and interaction \((LPS \times genotype, F(1,24) = 5.114, p = 0.0331; F(1,24) = 8.245, p = 0.0084)\) existed. Other pro-inflammatory cytokines Il6 and inflammasome component Nlrp3 also exhibited increased expression in WT mice upon LPS treatment, while in Mir146b-/− mice Il6 and Nlrp3 mRNA levels remained unchanged (Supplement Figure 3). Significant effects of LPS treatment was seen in both the mRNAs \((F(1,24) = 18.54, p = 0.0002; F(1,24) = 29.24, p < 0.0001)\), but not genotype on both mRNAs, while for Nlrp3, a significant effect of interaction \((F(1,24) = 20.63, p = 0.0001)\) was observed.

In WT mice, LPS administration reduced the level of anti-inflammatory cytokine Il10 \((p = 0.0036)\) but not Il13. Interestingly, in Mir146b-/− mice, the expressions of both cytokines were significantly increased (Figures 7E, F). Significant effects of LPS treatment \((F(1,24) = 10.09, p = 0.0041; F(1,24) = 56.31, p < 0.0001)\), genotype \((F(1,24) = 94.77, p < 0.0001; F(1,24) = 31.59, p < 0.0001)\), and interaction \((LPS \times genotype, F(1,24) = 75.30, p < 0.0001; F(1,24) = 16.68, p = 0.0004)\) were seen. Overall, miR-146b deficient mice had reduced levels of expression of pro-inflammatory cytokine genes and enhanced expression of anti-inflammatory genes upon LPS treatment compared with WT mice.

miR-146a is upregulated in the hippocampus and microglial cells isolated from miR-146b deficient mice

To answer the question of what mechanisms might be responsible for the observed attenuation of LPS-induced neuroinflammation in Mir146b-/− mice we measured the expression of miR-146a in these animals. First, we measured absolute miR-146a levels in the hippocampal tissues and secondly, we measured relative expression of miR-146a in microglial cells isolated from whole brain using percoll gradient. Experiments demonstrated significantly higher expression of miR-146a upon LPS challenge in the
hippocampal tissue of Mir146b-/− mice (p < 0.0001) as compared to WT animals (p = 0.0016) (Figure 8A). A significant effect of LPS treatment (F(1,12) = 106.0, p < 0.0001) but not genotype and interaction (LPS x genotype, F(1,12) = 10.74, p = 0.0066) was found. In isolated microglial cells, both WT and Mir146b-/− mice showed overexpression of miR-146a upon LPS administration. Welch’s ANOVA of miR-146a expression in microglial cells also demonstrated a significant effect on LPS (F(3,4.2) = 86.89, p = 0.0003), whereas post hoc analysis showed revealed much higher increase (p = 0.0006) in miR-146a upon LPS challenge in Mir146b-/− mice as compared with WT mice. It should be also noted that basal miR-146a expression in Mir146b-/− mice was also significantly (p = 0.001) higher than in WT mice (Figure 8B).
LPS-induced neuroinflammatory response is restored in double knockout Mir-146a/b-/– mice

To evaluate whether miR-146a upregulation is responsible for the observed attenuation of neuroinflammation in Mir146b-/– mice, additional experiments were performed on Mir-146a/b-/– mice. We assessed LPS-induced sickness behavior in these animals and measured the mRNA expression of pro-inflammatory cytokines Ccl5 and Tnf in the hippocampal tissues.

In Mir-146a/b-/– mice, LPS administration induced sickness behavior similar to WT mice. For body weight changes, Welch’s ANOVA showed significant effect LPS (F(3,15.3) = 76.2, p < 0.0001), whereas post hoc analysis showed a similar decrease in body weight in both WT and Mir-146a/b-/– mice (Figure 9A). For locomotor activity Welch’s ANOVA also showed significance (F(3, 8.75) = 21.26, p = 0.002) and post hoc analysis demonstrated significant decrease in locomotion in both WT and Mir-146a/b-/– mice (p < 0.05) and Mir-146a/b-/– mice (p = 0.01) (Figure 9B). Immobility time in tail suspension test was significantly increased in Mir-146a/b-/– mice and a trend toward increase was also seen in WT animals (Figure 9C). The lack of significance in WT animals is probably due to the insufficient number of animals in a group. Further gene expression analysis in Mir-146a/b-/– mice showed an increased expression of pro-inflammatory cytokines upon LPS challenge (Figures 9D, E). For Tnf expression, Welch’s ANOVA showed significant effect (F(3,5.61) = 5.1 p = 0.047) and Dunnett’s test showed a significant effect of LPS treatment in Mir-146a/b-/– mice. For Ccl5 expression, Welch’s ANOVA also demonstrated significant effect of LPS (F(3, 14.4) = 29.5, p < 0.0001) and Dunnett’s test showed a significant increase in both WT (p < 0.001) and Mir-146a/b-/– mice (p = 0.04). These data show that LPS induces neuroinflammatory response in double knockout Mir-146a/b-/– mice similar to those observed in WT mice.

LPS induced NF-κB activation, Ira1 expression and interferon regulatory factor 7 (IRF7) expression in Mir146b-/– mice

To explore further mechanisms of the observed LPS-induced upregulation of miR-146a in Mir146b-/– mice, we focused on the transcriptional regulators of miR-146a/b, NF-κB and Irf7/3.

As the expression levels of cytokines are NF-κB-dependent and NF-κB is the most important transcriptional regulator of miR-146a/b, we next assessed whether miR-146b deficiency may affect this pathway. The classical NF-κB pathway activation occurs via phosphorylation and following ubiquitination and degradation of IκB. The remaining NF-κB dimer (e.g., p65/p50 subunits) translocate to the nucleus, where it binds to the DNA consensus sequence of various target genes. Measuring p65 levels in the nuclear fraction reflects the level of activation of the NF-κB pathway (54). Therefore, we next isolated the nuclear fraction of hippocampal cells and measured p65 and histone-4 levels with western blot. In WT mice, LPS treatment induced significant NF-κB activation (p = 0.039) as evidenced by the increased levels of p65 in the nuclear lysate. In contrast, no significant increase in p65 levels was observed in nuclear lysates purified from Mir146b-/– mice upon LPS challenge (Figures 10A, B) and the whole blot picture is provided in the (Supplement Figure 4). For p65 levels, two-way ANOVA demonstrated...
significant effect of LPS treatment (F(1,10) = 15.3; p = 0.0029) and significant effect of interaction between treatment and genotype (F(1,10) = 4.98; p = 0.05) but no effect of genotype. We next analyzed mRNA expression of a miR-146a/b target, \textit{Irak1} and TLR4 receptor protein levels in the hippocampus of WT and Mir146b-/- mice after LPS treatment. Interestingly, mRNA expression of \textit{Irak1} was reduced in both WT and Mir146b-/- mice in response to LPS. However, the extent of \textit{Irak1} reduction was more prominent in WT (p < 0.0001) than Mir146b-/- mice (p = 0.0478) (Figure 10C). Significant effects of LPS treatment (F(1, 24) = 34.30, P < 0.0001) and genotype (F(1, 24) = 4.421, P = 0.0462), but not interaction were observed. As previous data have demonstrated that upregulated miR-146a can negatively affect TLR4 expression (55–57), we analyzed TLR4 expression in miR-146b deficient mice upon LPS administration. Lysates of hippocampal tissues probed for TLR4 demonstrated a significant increase in TLR4 protein levels upon LPS administration in WT animals but not in Mir146b-/- mice.
These data suggest that miR-146a-mediated ability of targeting TLR4 might be responsible for the observed attenuation of NF-kB activation in Mir146b-/- mice.

Next, we explored a possible role of another group of transcriptional regulators Irf3/7. For Irf3, two-way ANOVA did not demonstrate significant effect. Multiple comparisons test revealed a small but significant increase in expression upon LPS treatment only in Mir146b-/- mice (Supplement Figure 5). For Irf7, two-way ANOVA demonstrated highly significant effect of LPS treatment: (F(2,23) = 82.4, p < 0.001), significant effect of genotype: (F(2,23) = 11.9, p = 0.002), and significant effect of interaction: (F(2,23) = p = 0.02). Multiple comparisons test showed a significant increase in Irf7 expression upon LPS challenge in both WT (p < 0.001) and Mir146b-/- (p < 0.0001) mice (Figure 10D). Furthermore, LPS-induced changes in Irf7 expression were significantly (p < 0.001) higher in Mir146b-/- mice as compared with their WT littermates.
These data suggest that Irf7 is most probably responsible for the observed upregulation of miR-146a in Mir146b-/- mice.

Discussion

Previous research has demonstrated that miR-146 family members act as negative modulators of inflammation (12, 28, 31). Several other studies have also demonstrated that deficiency in miR-146a results in an exaggerated inflammatory response to the LPS challenge (18, 19, 58), whereas miR-146a overexpression reduces microglia mediated neuroinflammatory responses and inhibits sickness behavior (59, 60). Paradoxically, our study revealed that Mir146b-/- mice demonstrated attenuated neuroinflammatory response upon LPS challenge as compared with their WT littermates. Reduced neuroinflammatory status of Mir146b-/- mice upon LPS challenge was evidenced by the reduced intensity of sickness behavior and demonstrated less morphological characteristics of microglial activation. Although sickness behavior is believed to be associated with neuroinflammation, the impact of peripheral inflammatory reaction cannot be excluded (61, 62). Concordantly, flow cytometry experiments demonstrated an increased percentage of microglia in WT mice but not in Mir146b-/- mice upon LPS administration. In addition, the activation marker for microglial CD11b was decreased at basal levels in Mir146b-/- mice indicating that miR-146b deficiency causes lesser microglial activation. Furthermore, LPS mediated increased phagocytosis capacity in WT microglia and but not in Mir146b-/- mice.

In line with behavior studies and microglial status, LPS-mediated stimulation of the expression of pro-inflammatory cytokines Il1b, Ccl5, Tnf, Il1b, Il6 and Nlrp3 mRNAs was weaker in Mir146b-/- LPS mice compared to WT LPS animals. These data indicate that miR-146b deficient mice are more immunotolerant to the LPS-induced inflammatory signal than their WT littermates.

One possible explanation for a seemingly paradoxical consequence of miR-146b deficiency may come from the observed over-expression of miR-146a in these animals when treated with LPS. The increase in expression of miR-146a upon LPS challenge was evident in hippocampal tissues as well as in microglia isolated from the hippocampal tissue. Although the only marginal increase in miR-146a copy number in these animals was observed, the relevance of miR-146a over-expression in Mir146b-/- mice was confirmed by the experiments conducted on double knockout mice deficient for both miR-146a and miR-146b. Indeed, in these animals, LPS-induced sickness behavior and expression of pro-inflammatory cytokines were similar or even higher than those observed in WT animals.

It seems that blunted inflammatory response upon LPS challenge observed in Mir146b-/- mice is due to the reduced activation of NF-kB. The mechanisms of miR-146a-mediated reduction of neuroinflammatory response remains obscure. It seems unlikely that major regulatory activator of NF-kB, IraK is implicated in the observed reduced activity of NF-kB as reduction in the expression of IraK1 was higher in Mir146b-/- mice as compared with WT animals. More likely, reduced activation of NF-kB is due to the diminished ability of TLR4 to become upregulated in response to LPS. Indeed, several studies have demonstrated upregulation of TLR4 protein upon LPS challenge (63, 64). In our experiments, similar upregulation was also observed in WT animals and in contrast, Mir146b-/- mice TLR4 protein remained unchanged after LPS administration. It is known that TLR4 is a target of miR-146a (55–57) and thereby causing decreased activation of NF-kB and reduced inflammation.

To explain possible mechanisms of the observed miR-146a upregulation we next searched for transcription regulators such as interferon regulatory factor 3/7 (If3/7) responsible for miR-146a overexpression. There is evidence that If3/7 plays an essential role in the LPS-induced interferon-β gene expression and endotoxic shock (65) and overexpression of If3/7 suppressed inflammatory reaction upon LPS challenge (66). Indeed, our experiments demonstrated that If3 and, to a lesser extent, If3 become highly upregulated upon LPS challenge in miR-146b deficient mice. We, therefore, propose that upregulation of If3 leads to the over-expression of miR-146a, which in turn inhibits NF-kB activation leading to the blunted inflammatory response. The crosstalk between miR-146a and miR-146b in the regulation of neuroinflammation is summarized in Figure 11.

It should be noted that the mechanism by which miR-146b can regulate the expression of If3/7 remains unknown and needs to be studied in the future. In addition, a possible impact of other transcriptional regulators such as CCAAT-enhancer-binding-protein-β (C/EBPβ) in the observed overexpression of miR-146a in Mir146b-/- mice upon LPS treatment remains unknown. We also do not exclude the impact of systemic inflammation and peripheral miR-146b deficiency in the observed blunted neuroinflammatory response in miR-146b deficient mice. It is not excluded that miR-146b deficiency can promote invasion of the peripheral immune cells expressing miR-146a to the brain via disruption of the blood-brain-barrier (BBB). Wnt/β-catenin signaling is essential for maintaining the integrity of the adult BBB in physiological and pathological conditions (67) as its inhibition or deficiency causes BBB breakdown. Previous studies have shown that miR-146b induces silencing of Secreted frizzled-related protein 1 (SFRP1) which acts as an antagonist of Wnt signaling (68). Thus, miR-146b deficiency might induce indirect inhibition of Wnt/β-catenin signaling and weakness of BBB. This hypothesis, however, remains highly speculative as no direct studies on BBB permeability in miR146b deficient mice were conducted so far.

Conclusion

In the present study, we utilized different methods to examine LPS-induced neuroinflammation in miR-146b deficient mice. It was
found that LPS-induced neuroinflammation is attenuated in these animals and it was evidenced by the reduced signs of sickness behavior, and reduced activation of microglia. Gene and protein expression analysis revealed that LPS administration induced weaker upregulation of proinflammatory cytokines and NF-κB activation in the brain of Mir146b-/− mice compared to WT mice. The blunted neuroinflammatory reaction upon LPS challenge observed in Mir146b-/− mice is the most probably due to the compensatory over-expression of miR-146a. Over-expression of miR-146a is mediated by the induction of transcription regulator Irf7 and, to a lesser extent, Irf3 in the hippocampal tissue. Our data show the existence of crosstalk between miR-146a and miR146b in the regulation of neuroinflammation.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The animal study was reviewed and approved by Animal Experimentation Committee at the Estonian Ministry of Agriculture (no. 183 and 158, 2021).

Author contributions

KC: Designed and performed all experiments, writing - original draft, investigation, formal analysis. MJ: Performed behavioral animal experiments and perfusion and protein expression analysis. MG: Performed protein expression analysis and qPCR. LY: Performed behavior. TZ: Performed Iba1 immunohistochemistry. MP: Quantification of miRNA. NM and MB: construction of mice line. AR: Writing - review and editing, investigation supervision, project administration, funding acquisition. LT: Writing - review & editing, conceptualization, supervision, project administration, funding acquisition. AZ: Writing – original draft, review & editing, conceptualization, supervision, project administration, funding acquisition. All authors contributed to the article and approved the submitted version.

Funding

AZ is supported by the Estonian Research Council personal research funding team grant project No. PRG878. LT is supported by the Estonian Research Council-European Union Regional Developmental Fund Mobilitas Pluss Program No. MOBTT77 and AR is supported by European Regional Development Fund (Project No. 2014-2020.4.01.15-0012) and a personal grant from Estonian Research Council, PRG1259.
Acknowledgments

The authors would like to thank Anu Remm for helping with genotyping of Mir146b-/− mice and Kai Kiisand for providing histone antibody.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Lee H-M, Nguyen DT, Lu L-F. Progress and challenge of microRNA research in immunity. Front Genet (2014) 5:178. doi: 10.3389/fgene.2014.00178
2. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol (2016) 16:22–34. doi: 10.1038/nri.2015.5
3. Sleta IA, Booth SA. MicroRNAs in neuroinflammation: implications in disease pathogenesis, biomarker discovery and therapeutics applications. Non-Coding RNA (2019) 5:35. doi: 10.3939/nrrna500035
4. So AY, Zhao JL, Baltimore D. The Yin and Yang of micro RNA s: leukemia and beyond. Leukemia (2011) 25:54–60. doi: 10.1038/leu.2010.242
5. Maito MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of inflammation: what controls its onset? Front Immunol (2016) 7:160. doi: 10.3389/fimmu.2016.00160
6. O’Connell RM, Rao DS, Baltimore D. microRNA regulation of innate responses. Annu Rev Immunol (2012) 30:295–312. doi: 10.1146/annurev-immunol-020711-075613
7. Bartel DP. Metazoan micrornas. Cell (2004) 116:281–97. doi: 10.1016/S0092-8674(04)00068-3
8. Xu X, Guo Y, Li J, Xiao L, Zhang M, Zheng X, et al. The microRNA-155-5p promotes neuroinflammation and central sensitization via inhibiting SIRT1 in a nitroglycerin-injected chronic migraine mouse model. J Neuroinflammation (2021) 18:1–17. doi: 10.1186/s12974-021-02342-5
9. O’Connell RM, Rao DS, Baltimore D. microRNA regulation of innate responses. Annu Rev Immunol (2012) 30:295–312. doi: 10.1146/annurev-immunol-020711-075613
10. Wittkopp PK, Baur K, Ziebell K, Schuhmacher S, Mack DF, Gehr HW, et al. Genetic and evolutionary imperative to modern treatment target. Annu Rev Immunol (2019) 33:59–85. doi: 10.1146/annurev-immunol-022618-021858
11. Deng Y, Zhang J, Sun X, Ma G, Luo G, Miao Z, et al. MicroRNA-146b is a novel microRNA with neuroprotective effects by inhibiting p38 MAPK1 signal pathway in chronic cerebral ischemia. PLoS One (2014) 9(12):e117480. doi: 10.1371/journal.pone.0117480
12. Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, et al. The impact of miR-146a on arteriogenesis. J Invest Dermatol (2016) 136:1815–24. doi: 10.1111/jid.14064
13. Paterson MR, Kriegel AJ. MiR-146a/b: A family with shared seeds and shared functions in immunity. Front Immunol (2014) 5:178. doi: 10.3389/fimmu.2014.00178
14. Hermann H, Runnel T, Aab A, Raivos K, Ernberg J, van der Helm L, et al. MicroRNA-146a/b promotes T-cell adhesion through repression of multiple targets to inhibit NF-kB activation. J Cell Mol Med (2015) 19:3412–23. doi: 10.1111/jcm.12532
15. Paterson MR, Kriegel AJ. MiR-146a/b: A family with shared seeds and shared functions in immunity. Front Immunol (2014) 5:178. doi: 10.3389/fimmu.2014.00178
16. Hermann H, Runnel T, Aab A, Baurecht H, Rodriguez E, Magilnick N, et al. MicroRNA-146a negatively regulates T-cell adhesion through repression of multiple targets to inhibit NF-kB activation. J Cell Mol Med (2015) 19:3412–23. doi: 10.1111/jcm.12532
17. Taganov KD, Boldin MP, Chang K-J, Baltimore D. NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci (2006) 103:12481–6. doi: 10.1073/ pnas.0605298103
18. Saba S, Sorensen DL, Booth SA. MicroRNA-146a: A dominant, negative regulator of the innate immune response. Front Immunol (2014) 3:578. doi: 10.3389/fimmu.2014.00578
19. Taganov KD, Boldin MP, Chang K-J, Baltimore D. NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci (2006) 103:12481–6. doi: 10.1073/pnas.0605298103
20. Saba S, Sorensen DL, Booth SA. MicroRNA-146a: A dominant, negative regulator of the innate immune response. Front Immunol (2014) 3:578. doi: 10.3389/fimmu.2014.00578
21. Zhang J, Sun X, Ma G, Luo G, Miao Z, et al. MicroRNA-146b is a novel microRNA with neuroprotective effects by inhibiting p38 MAPK1 signal pathway in chronic cerebral ischemia. PLoS One (2014) 9(12):e117480. doi: 10.1371/journal.pone.0117480
22. Chithanathan K, Somelar K, Jürgenson M, Zarkowska T, Peryiasamy K, Yan L, et al. Enhanced cognition and neurogenesis in miR-146b deficient mice. Cells (2022) 11:2002. doi: 10.3390/cells11132002
23. Fregaie J, Morceau S, Pali A, Nguyen LS, Oury F, Colleaux L. Loss of the neurodevelopmental disease-associated gene miR-146a impairs neural progenitor differentiation and causes learning and memory deficits. Mol Autism (2020) 11:1–14. doi: 10.1186/s13229-020-00328-3
24. Cui L, Yu Y, Ma G, Wang Y, Cai Y, Liu S, et al. A functional polymorphism in the promoter region of microRNA-146a is associated with the risk of Alzheimer disease and the rate of cognitive decline in patients. PLoS One (2014) 9:e89019. doi: 10.1371/journal.pone.0089019
25. Cui L, Tao H, Wang Y, Liu Z, Xu Z, Zhou H, et al. A functional polymorphism of the microRNA-146a gene is associated with susceptibility to drug-resistant epilepsy and seizures frequency. Seizure (2015) 27:650–6. doi: 10.1016/j.seizure.2015.02.032
26. Jagathari A, Singh T, Mishra S, Shankar J, Yadav S. Coordinated action of miR-146a and parkin gene regulate rotenone-induced neurodegeneration. Toxicol Sci (2020) 176:433–45. doi: 10.1093/toxsci/kfaa066
27. Ansari A, Maffioletti E, Milanesi E, Marzillosi M, Frissone GB, Blin O, et al. miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer’s disease. Neurobiol Aging (2019) 82:102–9. doi: 10.1016/j.neurobiolaging.2019.06.005
28. Sharna N, Verma R, Kumawat KL, Basu A, Singh SK. miR-146a suppresses cellular immune response during Japanese encephalitis virus JArO53498 strain infection in human microglial cells. J Neuroinflammation (2015) 12:1–16. doi: 10.1186/s12974-015-0249-0
29. Araiwa E, Fujita K, Iyer A, Zurolo E, Van Vliet E, et al. Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Eur J Neurosci (2010) 31:1100–7. doi: 10.1111/j.1460-9568.2010.07122.x
30. Yang G, Zhao Y. Overexpression of mir-146b-5p ameliorates neonatal hypoxic ischemic encephalopathy by inhibiting iNOS/NO signaling. Yonsei Med J (2020) 61:660. doi: 10.3349/ymj.2020.61.8.660

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.996415/full#supplementary-material
31. Bokobza C, Joshi P, Schang A, Csaiba Z, Faivre V, Montanié A, et al. miR-146b protects the perinatal brain against microglia-induced hypomyelination. *Ann Neurol* (2022) 91:48–65. doi: 10.1002/ana.26263

32. Jürgensen M, Assumr-Helm A, Zharovskaya A. Partial reduction in neural cell adhesion molecule (NCAM) in heterozygous mice induces depression-related behaviour without cognitive impairment. *Brain Res* (2012) 1447:106–18. doi: 10.1016/j.brainres.2012.01.056

33. Li Z, Ma L, Kuleszka N, Völker V, Tian L. Microglia are polarized to M1 type in high-amyloid inbred mice in response to lipopolysaccharide challenge. *Brain Behav Immun* (2014) 38:237–48. doi: 10.1016/j.bbi.2014.02.008

34. Piriainen S, Chithanathan K, Buhtki K, Pirisalu M, Savage JC, Tremblay M, et al. Microglia contribute to social behavioral adaptation to chronic stress. *Glia* (2021) 69:2459–73. doi: 10.1002/glia.24053

35. Hovens IB, Nyakas C, Schoemaker RG. A novel method for evaluating microglial activation using ionized calcium-binding adaptor protein-1-staining cell body to cell size ratio. *Neurommune Neuroinflamm* (2014) 1:182–9. doi: 10.1186/2347-8659.139719

36. Jürgensen M, Zharkovskaya T, Noortoerts A, Morozova M, Beniaishvili A, Zapolski M, et al. Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-β-predominant mouse model of Alzheimer’s disease. *J Pharm Pharmcol* (2019) 71:1695–705. doi: 10.1111/jpp.13165

37. Agalave NM, Lane BT, Mody PH, Szabo-Pardi TA, Burton MD. Isolation, culture, and downstream characterization of primary microglia and astrocytes from adult rodent brain and spinal cord. *J Neurosci Methods* (2020) 340:108742. doi: 10.1016/j.jenmef.2020.108742

38. Shi F-J, Xie H, Zhang C-Y, Qin H-F, Zeng X-W, Lou H, et al. Iba-1 protein expression a sensitive marker for microglia activation in experimental diabetic retinopathy? *Diabetes Metab* (2016) 42:82–8. doi: 10.1016/j.dibi.2015.02.005

39. Biesmans S, Meert TF, Bouwknecht JA, Acton PD, Davoodi N, De Haes P, et al. Systemic immune activation leads to neuroinflammation and memory impairment during chronic neurodegeneration. *Brain Res* (2022) 91:48–55. doi: 10.1016/j.brainres.2022.03.004

40. Hines DJ, Choi HB, Hines RM, Phillips AG, MacVicar BA. Prevention of microglia M1 polarization during olfactory development and olfactory dysfunction in high-anxiety inbred mice in response to lipopolysaccharide challenge. *Behav Immun* (2014) 38:237–48. doi: 10.1016/j.beini.2014.02.011

41. Akaihama H, Nishimura T, Kondo H, Ikeda K, Hayashi Y, McGee PL. Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer’s disease and amyotrophic lateral sclerosis. *Brain Res* (1994) 639:171–4. doi: 10.1016/0006-8993(94)91779-5

42. Gómez-Nicolàs D, Fransen NL, Suzzi S, Perry VH. Regulation of microglial proliferation during chronic neurodegeneration. *J Neurosci* (2013) 33:2481–93. doi: 10.1523/JNEUROSCI.4440-12.2013

43. Chithanathan K, Xuan P-L, Hickey MA, Tian L. Enhanced anxiety and olfactory microglial activation in early-stage familial Alzheimer’s disease mouse model. *Biology* (2022) 11:938. doi: 10.3390/biology11060938

44. Maguire O, Collins C, O’Loughlin K, Miezcznikowski J, Minderman H. Quantifying nuclear p65 as a parameter for NF-κB activation: Correlation between ImageStream cytomtery, microscopy, and Western blot. *Cytometry A* (2021) 79:461–9. doi: 10.1002/cya.21068

45. Yang K, He YS, Wang QX, Lu L, Chen QJ, Qi L, et al. MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. *FEBS Lett* (2011) 585:854–60. doi: 10.1016/j.febslet.2011.02.009

46. Liu G-J, Zhang Q-R, Gao X, Wang H, Tao T, Gao Y-Y, et al. MiR-146a ameliorates hemoglobin-induced microglial inflammatory response via TLR4/IRAK1/TRAF6 associated pathways. *Front Neurosci* (2020) 14:311. doi: 10.3389/fnins.2020.00331

47. Xiao Q, Zhu X, Yang S, Wang J, Yin B, Song J, et al. LPS induces CXCL16 expression in HUVECs through the miR-146a-mediated TLR4 pathway. *Int Immunopharmacol* (2019) 79:143–9. doi: 10.1016/j.intimp.2019.01.011

48. Zhang Q-R, Qing Y-F, Yin C-C, Zhou L, Liu X, Mi Q-S, et al. Mice with miR-146c deficiency develop severe gouty arthritis via dysregulation of TRAF6, IRAK1 and NALP3 inflammasomes. *Arthritis Res Ther* (2018) 20:1–9. doi: 10.1186/s13075-018-1546-7

49. Liu C-P, Zhong M, Sun J-X, He J, Gao Y, Qin F-X. MiR-146a reduces depressive behavior by inhibiting microglial activation. *Mol Med Rep* (2021) 18:97–102. doi: 10.4103/mmr.mmr.2021.895429

50. Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA. Role of MiR-146a in the regulation of the innate immune response and cancer. *Biochem Soc Trans* (2008) 36:1211–5. doi: 10.1042/BST0361211

51. Dantzler R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* (2008) 9:46–56. doi: 10.1038/nrn2297

52. Dantzler R. Cytokine-induced sickness behavior: mechanisms and implications. *Annu N Y Acad Sci* (2001) 933:222–34. doi: 10.1111/j.1749-6632.2001.tb00838.x

53. Wang P, Han X, Mo B, Huang G, Wang C. LPS enhances TL14 expression and IFN-γ production via the TLR4/IRAK1/NF-κB signaling pathway in rat pulmonary arterial smooth muscle cells. *Mol Med Rep* (2017) 16:3111–6. doi: 10.3892/mmr.2017.6082

54. Xiao Q, Zhu X, Yang S, Wang J, Yim B, Song J, et al. LPS induces CXCL16 expression in HUVECs through the miR-146a-mediated TLR4 pathway. *Int Immunopharmacol* (2019) 79:143–9. doi: 10.1016/j.intimp.2019.01.011

55. Zhang Q-R, Qing Y-F, Yin C-C, Zhou L, Liu X, Mi Q-S, et al. Mice with miR-146c deficiency develop severe gouty arthritis via dysregulation of TRAF6, IRAK1 and NALP3 inflammasomes. *Arthritis Res Ther* (2018) 20:1–9. doi: 10.1186/s13075-018-1546-7

56. Liu C-P, Zhong M, Sun J-X, He J, Gao Y, Qin F-X. MiR-146a reduces depressive behavior by inhibiting microglial activation. *Mol Med Rep* (2021) 18:97–102. doi: 10.4103/mmr.mmr.2021.895429

57. Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA. Role of MiR-146a in the regulation of the innate immune response and cancer. *Biochem Soc Trans* (2008) 36:1211–5. doi: 10.1042/BST0361211

58. Dantzler R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* (2008) 9:46–56. doi: 10.1038/nrn2297

59. Dantzler R. Cytokine-induced sickness behavior: mechanisms and implications. *Annu N Y Acad Sci* (2001) 933:222–34. doi: 10.1111/j.1749-6632.2001.tb00838.x